{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=10",
    "query": {
      "intervention": "Combination Agent 2",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 3607,
    "total_pages": 361,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T06:18:17.035Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02901275",
      "title": "Enhancing Medication-based Analgesia in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain",
        "Cannabis",
        "Opioid Use, Unspecified"
      ],
      "interventions": [
        {
          "name": "Within-subject test of blinded study medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 29,
      "start_date": "2016-12",
      "completion_date": "2020-03-23",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02901275"
    },
    {
      "nct_id": "NCT00470184",
      "title": "Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2006-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2013-11-25",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470184"
    },
    {
      "nct_id": "NCT01540500",
      "title": "Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Tasimelteon",
          "type": "DRUG"
        },
        {
          "name": "Fluvoxamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2012-02",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2014-02-17",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "Springfield, Missouri",
      "locations": [
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540500"
    },
    {
      "nct_id": "NCT04543071",
      "title": "Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Adenocarcinoma of the Pancreas",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Motixafortide",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2020-11-09",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04543071"
    },
    {
      "nct_id": "NCT02727998",
      "title": "Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Posttraumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 28,
      "start_date": "2015-12",
      "completion_date": "2021-11-28",
      "has_results": true,
      "last_update_posted_date": "2022-10-17",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02727998"
    },
    {
      "nct_id": "NCT00002177",
      "title": "A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-05",
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2011-04-14",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002177"
    },
    {
      "nct_id": "NCT04747912",
      "title": "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoblastic Leukemia",
        "Acute Lymphoblastic Leukemia",
        "ph+ Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Inotuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Ponatinib",
          "type": "DRUG"
        },
        {
          "name": "Purinethol (6-Mercaptopurine)",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-03-02",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04747912"
    },
    {
      "nct_id": "NCT04418895",
      "title": "Neoadjuvant Therapy for Localized Rectal Adenocarcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rectal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Chemoradiation",
          "type": "OTHER"
        },
        {
          "name": "short course radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "CAPOX",
          "type": "DRUG"
        },
        {
          "name": "fluoropyrimidine +/- oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-08-13",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-10",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418895"
    },
    {
      "nct_id": "NCT00007332",
      "title": "Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC(2)120(B,MN)GNP (vCP1452)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MN rgp120/HIV-1 and GNE8 rgp120/HIV-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 330,
      "start_date": null,
      "completion_date": "2003-04",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00007332"
    },
    {
      "nct_id": "NCT06736704",
      "title": "SNV4818 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "SNV4818",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pikavation Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2025-02-20",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-11-16T06:18:17.035Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06736704"
    }
  ]
}